A great day for Exelixis

This is just to inform that Europe has approved Cabometyx® (cabozantinib) tablets as a monotherapy for hepatocellular carcinoma (HCC). As you know, Cabometyx belongs to Exelixis (EXEL). Today Exelixis announced that its partner, Ipsen, received approval of the drug, from the European Commission (EC), to be used in adults who have HCC and have previously been treated with sorafenib.

This approval allows for the marketing of Cabometyx in this indication in all 28 member states of the European Union, Norway and Iceland.

Under the terms of the Collaboration . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.